Genmab — August 2016
-
"
The Copenhagen, Denmark-based biotech now lists J&J, Novartis ($NVS) and Novo Nordisk ($NVO) alongside Gilead on the list of top drugmakers that have licenses to use its bispecific antibody platform. In keeping with the Gilead agreement, the deals are heavily backloaded but have the potential to be tidy earners for Genmab". -
-
Lyder som en god idé.
-
Er gået short i biotekindekset: https://play.borsen.dk/social/57ac478ed99b63192e1f0f67
-
Bemærk hans slutreplik omkring at gå short i Genmab.
-
så gutten lægger sig short baseret på en 12 måneder gammel nyhed....
-
Til alle medicinnørderne. Prøv at læse skribent KongFais indlæg om Prostvac i Bavarianchatten. Den gut er godt inde i materien.
-
well, Hillary's tweet var en reaktion på Turing og Valeants meget lidt sympatiske tilgang til prissætning - Jeg tror ikke, at den kommer forbi igen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind